Retroviral integrases catalyze two reactions, 3' processing of viral DNA ends, followed by integration of the processed ends into chromosomal DNA. X-ray crystal structures of integrase-DNA complexes from prototype foamy virus, a member of the spumavirus genus of Retroviridae, have revealed the structural basis of integration and how clinicallyrelevant integrase strand transfer inhibitors work. Underscoring the translational potential of targeting viralhost interactions, small molecules that bind at the host factor LEDGF/p75 binding site on HIV-1 integrase promote dimerization and inhibit integrase-viral DNA assembly and catalysis. Here we review recent advances in our knowledge of HIV-1 DNA integration, as well as future research directions.
The early events of retroviral replication take place within the context of nucleoprotein complexes that are derived from the core of the infecting virus particle (1, 2) . Within the confines of the reverse transcription complex (RTC) 2 , the reverse transcriptase enzyme copies single-stranded viral RNA into a linear double stranded DNA molecule containing a copy of the long terminal repeat (LTR) sequence at each end. The viral integrase (IN) engages the LTR ends prior to catalyzing two spatially and temporally distinct chemical reactions. Soon after their synthesis (3), IN sitespecifically processes each LTR end adjacent to an invariant CA dinucleotide (4, 5) , yielding CA OH 3'-hydroxyl groups that serve as the nucleophiles for the second reaction, DNA strand transfer. Because the viral replication intermediate at this point gains the ability to catalyze DNA strand transfer activity, 3' processing operationally marks the transition of the RTC to the preintegration complex (PIC) (Fig. 1 ). In the strand transfer step, IN utilizes the 3'-oxygen atoms to cut chromosomal DNA in staggered fashion and simultaneously join the viral DNA ends to the 5'-phosphates of the target DNA (4, 6, 7) . The resulting DNA recombination intermediate, with unjoined viral DNA 5' ends, is repaired by host cell enzymes to yield the integrated provirus flanked by the duplication of the sequence of the staggered DNA cut (Fig. 1) . The spumaviruses, which comprise one of seven Retroviridae genera, are an exception to this generalized scheme, as DNA synthesis is largely complete prior to target cell infection (8) . Research on the functionality of the active nucleoprotein complexes that mediate HIV-1 DNA integration has led to the development of antiviral inhibitors that target the IN and block integration.
Retroviral INs belong to a superfamily of proteins known as the retroviral IN superfamily (RISF) that contains other nucleic acid metabolizing enzymes such as RNase H, RuvC, bacteriophage MuA transposase, and the nuclease component of the RISC complex Argonaute (9) . Common features of these enzymes are the RNase H-fold adopted by their catalytic domains, and active sites composed of electronegative Asp and Glu side chains (9,10). 3' Processing and DNA strand transfer are in-line bimolecular nucleophilic substitution (S N 2) reactions (7), and the catalytic site residues coordinate the positions of two Mg 2+ ions to activate the attacking nucleophile (the oxygen atom of a water molecule for 3' processing; the 3'-hydroxyl of viral DNA for strand transfer) and destabilize the scissile phosphodiester bonds (11-13) ( Fig. 1 and 2 ). Sequence database analysis has indicated the presence of a much larger DD(E/D) superfamily named for catalytic triad amino acid signatures, though in many cases verification of active site domain RNase H folds and functional active site residues awaits validation (14) .
All retroviral IN proteins share three common domains, the N-terminal domain (NTD), catalytic core domain (CCD), and Cterminal domain (CTD) (for a recent review on domains and IN structure, see ref. 15 ). The CCD as mentioned adopts an RNase H fold, harboring the D,D-X 35 -E catalytic triad common to all retroviral and retrotransposon INs, as well as certain bacterial transposase proteins (10, 16, 17) . The NTD adopts a helix-turn-helix fold, utilizing conserved His and Cys residues to bind a single Zn 2+ ion whereas the positively-charged CTD adopts an SH3 fold. Crystal structures of the prototype foamy virus (PFV) IN in complex with DNA revealed a fourth domain upstream from the NTD, termed the Nterminal extension domain (NED) (18) ( Fig.   2A ). Based on amino sequence alignment, the IN proteins from two additional genera, the gammaretroviruses and epsilonretroviruses, are predicted to harbor NEDs.
Retroviral

IN-DNA nucleoprotein complexes
The identification of specific nucleoprotein complexes that mediate the transposition of mobile DNA elements such as phage Mu and Tn10 (19) predated analogous work with retroviruses, so it is convenient to adopt DNA transposon terminology to describe the salient retroviral complexes. The stable synaptic complex (SSC) is formed upon IN binding to the LTR DNA ends, and 3' processing yields the cleaved donor complex (CDC; donor refers to mobile element DNA, which for retroviruses is the viral DNA). Engagement of chromatin acceptor or target DNA by the CDC in the cell nucleus yields the target capture complex (TCC), and integration of the viral DNA 3' ends yields the strand transfer complex (STC) (Fig. 1) . The 'intasome' term, which was originally used to describe the higher-order nucleoprotein complex between bacteriophage lambda integrase (Int; note phage lambda and retroviruses integrate through fundamentally different mechanisms; ref. 20) and lambda substrate DNA (21), was first adopted by the retrovirus field to describe an assembly responsible for the approximate 250 bp functional footprints at the LTR end regions of Moloney murine leukemia virus (Mo-MLV) and HIV-1 PICs (22,23). The term has subsequently been used to describe the heart of the DNA recombination machine, composed of a tetramer of IN protein and two viral DNA ends (18) ( Fig. 2A, right) . The SSC, CDC, TCC, and STC accordingly represent different stages of the retroviral intasome that correspond to the distinguishable nucleoprotein complexes along the integration pathway ( Fig. 1 and 2 X-ray crystal structures of functional PFV intasomes have yielded unprecedented details on the mechanism of retroviral DNA integration (13, 18, 26) . The intasome is composed of a dimer of IN dimers, with each monomer within the dimer playing a distinct role ( Fig. 2A) . The inner monomer (colored green in Fig. 2A (Fig. 2A, right) . Such trans configurations, which can be found throughout the RISF (32,33) as well as in other DNA recombination systems (34), help to ensure coordinated activity by a multimer of recombinase protein on a pair of participating DNA strands. An outstanding question with the PFV structure is the role of the 'missing' domains of the outer IN molecules. The visualized domains of the tetramer remain largely unchanged as the SSC progresses to the STC (Fig. 2B ) (13, 26) . Because the outer IN domains remain unresolved during this transition (Fig. 2B) , it seems they are unlikely to play direct roles in DNA recombination and are more likely to help support the architecture of the inner pair of workhorse monomers.
Recombinant PFV IN was amenable to intasome structural biology due to its inherent solubility in relatively low ionic strength buffer and its favorable DNA recombination properties (18, 35, 36) . The enzyme importantly integrates relatively short (≥ 16 bp) DNA oligonucleotide mimics of the U5 LTR end into both strands of target DNA separated by 4 bp, the spacing of the target site duplication observed during PFV infection (36 (13) . Consistent with the observation that the NTD works in trans with the CCD to catalyze 3' processing activity (27,28), Li and colleagues demonstrated that a single HIV-1 DNA end can moreover be processed and integrated in the context of the intasomal tetramer in vitro (24). Such asymmetry may very well account for the different rates at which the U3 versus U5 ends of the HIV-1 LTR are processed during acute infection (3) as well as for the reasonable titers of single LTR end mutant viruses (53,54), where INmediated integration of the wild type end presumably templates subsequent hostmediated integration of the mutant viral DNA end (55,56). Skalka and colleagues have interestingly reported a novel 'reaching dimer' structure for avian sarcoma virus IN protein based on small angle X-ray scattering and chemical cross-linking that mimics the extended inner monomers of the PFV intasome (57). Though missing the canonical CCD-CCD interface, the reaching dimer nevertheless seemingly affords IN domain cis/trans relationships consistent with solution measures of 3' processing activity (27,28). Additional work is required to determine if the reaching dimer plays a physiological relevant role in catalyzing 3' processing activity, or in the assembly of the functional IN tetramer.
IN strand transfer inhibitors (INSTIs)
The establishment of DNA oligonucleotide-based HIV-1 IN 3' processing and DNA strand transfer assays (37,58) led to multi-well plate formats amenable for small molecule library screening (59-61). As alluded to in the previous section, catalysis under these conditions occurs in large aggregate assemblies more so than discrete, soluble complexes (35, 62) . Early hits included polyanions, which could disrupt the binding of positively-charged HIV-1 IN to DNA in a non-specific manner, and accordingly failed to effectively inhibit integration during HIV-1 infection or the activity of PICs extracted from infected cells (63) . Reconfiguring assay design to more faithfully recapitulate PIC biology by querying DNA strand transfer activity after pre-binding IN to preprocessed LTR DNA (64) in large part overcame this undesirable outcome, leading to the identification of diketo acid (DKA) compounds that specifically inhibited strand transfer activity in vitro and during HIV-1 infection (65) . Likely due to similar two metal ion-dependent active sites, DKAs are also potent hepatitis C virus RNA polymerase inhibitors and raltegravir (RAL), a pyrimidinone carboxamide, came from utilizing both enzymes in DKA optimization trials (66) . RAL, the sole licensed HIV-1 IN inhibitor to date, has become a mainstay antiviral agent since its introduction into the clinic in October 2007.
Potent INSTIs harbor two critical chemical moieties: hetero atom clusters reminiscent of the oxygen-based DKA pharmacophore, and a halo-benzyl side chain (Fig. 3A) . The similar chemical nature of amino acid carboxylate side chains and DKAs led to the suggestion that the drug moieties engage bound-metal ion at the IN active site (67) , results subsequently verified through co-crystallization of INSTIs with the PFV CDC (18,68,69). The crystal structures also revealed the role of the halobenzyl groups, which is to supplant the adenosine ring of the terminal deoxyadenylate residue at the processed LTR end and concordantly eject the nucleotide with its associated 3'-OH strand transfer nucleophile from the enzyme active site (18,68,69) (Fig. 3B) . INSTI engagement of the IN active site within the PFV CDC clashes with the position of the scissile dinucleotide at the uncleaved LTR end in the analogous SSC structure (Fig. 3C) , accounting for INSTI specificity to inhibit strand transfer activity over 3' processing activity (13) .
Resistance to RAL arises through one of three predominant pathways that include changes at HIV-1 IN amino acid residues Tyr143, Gln148, and Asn155 (70) . The amino acid sequences of the HIV-1 and PFV IN CCDs are 22% identical, and crystal structures of PFV intasomes harboring wild type or drug resistance changes, with or without bound drug, have helped explain the structural basis of HIV-1 drug resistance (18, 68, 69) . RAL in particular is unlikely to directly contact the side-chains of resistance substitutions that occur at positions 148 or 155 (45) . Instead, the substitutions appear to subtly affect local active site geometry, such that binding of the drug to mutant enzymes requires significant energetically unfavorable rearrangement of the IN CCD (68) . Consistent with this interpretation, resistance changes correlate with significant increases in drug dissociation rates from these enzymes (71) . The PIC harbors a unique enzymatic antiviral target: formed through IN processing of the LTR ends in the cytoplasm, the functional CDC must persist for sufficient time to accommodate PIC nuclear import, chromatin targeting, and IN strand transfer activity (Fig. 1) , which would require a few hours to days, depending on the activation state of the target cell. When dissociation constants are significantly longer than PIC half-life, CDCspecific drugs like INSTIs theoretically afford a 'one-shot kill' mechanism (72).
3' Processing and integration of modeled PFV LTR DNA has recently been followed in crystallo, allowing unprecedented visualization of the reaction mechanisms (13) (Fig. 2B) . Overlaying the position of RAL in the PFV CDC co-crystal structure with the respective 3' processing and strand transfer nucleophiles and scissile phosphodiester bonds from the SSC and TCC structures moreover revealed impressive similarities in positions of salient oxygen atoms (Fig. 3C) . The oxygen of the hetero atom cluster distal from the halobenzyl group mimics the attacking water nucleophile during processing (labeled W nuc in Fig. 3C ) and a bridging oxygen atom of the target phosphodiester bond during strand transfer. Vice versa, the proximal oxygen mimics the positions of the attacking 3'-OH nucleophile for DNA strand transfer and a bridging oxygen atom of the scissile phosphodiester bond during processing (Fig.  3C ). These data are fully consistent with the reversible 'ping-pong' role played by the two metal ions during RNase H catalysis (73) and furthermore suggest novel ways by which INSTIs could be modified to increase drug potency (13) . Dolutegravir (DTG; Fig. 3A ) is a promising second-generation INSTI that retains activity against many RAL-resistant viruses (69) . Co-crystallization with the PFV CDC revealed an extended linker region between the metal-binding hetero atoms and the halo-benzyl arm that allowed the drug to intimately contact the viral LTR end and IN β4-α2 loop region (69) (Fig. 3B) , likely contributing to the slower dissociation of DTG versus RAL from HIV-1 IN-LTR complexes in vitro (71) . The relative difficulty in selecting for DTG-resistant viruses ex vivo (47) suggests that the generation of resistance in vivo might occur less frequently than what has been seen with RAL. If so, such differences should be forthcoming over the next year or two as DTG segues into the AIDS clinic.
IN binding host factors and allosteric IN inhibitors (ALLINIs)
Numerous host factors have been described to bind to HIV-1 IN (see references 74 and 75 for recent reviews). Of these, LEDGF/p75 has been determined to play a vital role in viral DNA integration (reviewed in 76, 77) .
The different genera of retroviruses differentially target particular aspects of host cell chromatin during viral DNA integration (ref. 78 for review). Lentiviruses like HIV-1 preferentially integrate along the bodies of active genes, although integration negatively correlates with the uppermost levels of transcriptional activity (79) . Mo-MLV, a gammaretrovirus, also favors genes, but by contrast to HIV-1 favors promoters over internal regions (80) . Although the mechanisms that underlie different retroviral preferences for particular chromatin features during integration are largely unknown, the lentiviral preference to integrate along the bodies of active genes is largely determined by LEDGF/p75 (76, 77) .
LEDGF/p75 primarily acts as a bifunctional molecular tether: N-terminal elements that harbor a PWWP domain and a pair of AT-hook DNA binding motifs confer constitutive chromatin binding activity (81, 82) , whereas a C-terminally located INbinding domain (IBD) engages lentiviral IN protein (83, 84) . The overall efficiency of HIV-1 integration is reduced by as much as 10-fold in cells depleted for LEDGF/p75 content by RNA interference (85, 86) or gene knockout (87, 88) . Though LEDGF/p75 cofractionates with PICs extracted from HIV-1-infected cells (89) , PICs made in knockout cells display normal levels of DNA strand transfer activity in vitro (88) . LEDGF/p75 therefore plays no apparent role in the regulation of IN catalysis prior to chromatin engagement.
Concordantly, order-ofaddition experiments reveal that effective IN activity requires LTR substrate binding prior to LEDGF/p75 binding in vitro (46, 90) . It therefore seems that HIV-1 PICs most likely engage LEDGF/p75 as a chromatin component, where it preferentially associates along gene bodies (91) . LEDGF/p75-bound IN is then activated for strand transfer in the local vicinity. The mechanism that underlies the chromatin distribution of LEDGF/p75 is unknown, but predictably relies on engagement of specific histone modifications by the N-terminal PWWP domain (92, 93) .
The LEDGF/p75 IBD is a pseudo HEAT repeat analogous topology (PHAT) domain composed of two copies of a helixhairpin-helix HEAT (named for Huntingtin, elongation factor 3, subunit A of phosphatase 2A, yeast PI3 kinase) repeat (94) , and residues Ile365 and Asp366 at the tip of the N-terminal hairpin nestle into a cleft at the IN CCD-CCD interface (95) (Fig. 4A) . Through an impressive example of structure-based drug design, Debyser and colleagues identified a series of 2-(quinolin-3-yl)acetic acid derivatives that mimicked the positions of Ile365 and Asp365 in silico, and inhibited IN-LEDGF/p75 binding in vitro and HIV-1 replication in cell culture (96) . Although one of their more potent compounds, LEDGIN-6, did not inhibit IN 3' processing activity in vitro, BoehringerIngelheim (BI) identified a remarkably similar series of compounds using a high throughput screen for HIV-1 IN 3' processing activity (97) (Fig. 4B ). Due to this apparent discrepancy, LEDGIN-6 was compared to BI-1001 in a series of assays, which revealed the compounds similarly inhibit IN 3' processing and DNA strand transfer activities in the absence of added LEDGF/p75 protein (98) . Concurrent work using more potent derivatives including GS-A from Gilead Sciences, Inc. (Fig. 4B) , verified host factor independent inhibition of IN catalytic function (99, 100) . Because the compounds engage the IN CCD at the host factor binding cleft (Fig. 4C) distal from the active site (Fig. 4A) , they are bona fide allosteric inhibitors of enzyme activity. The compounds apparently stabilize an inactive dimeric form of IN, thereby preventing proper assembly of the HIV-1 SSC in vitro (98-100). They also display steep dose response curves during virus infection, which is indicative of a cooperative antiviral mechanism (98). X-ray structures of ALLINI-CCD co-crystals moreover indicate that antiviral potency is dictated by the strength of the interaction (Fig. 4C) , suggesting that further drug modifications could increase efficacy. Although the underlying mechanisms of cooperative drug behavior during HIV-1 infection are not entirely clear, inhibition of both intasome assembly and intasome-LEDGF/p75 interaction are reasonable possibilities (98) (99) (100) . Virus produced in the presence of drug is unable to initiate a new round of infection 3 (100), indicating that inhibition of steps in the HIV-1 lifecycle that precede integration might contribute to the multimode mechanism of action of these intriguing compounds.
Conclusions
The retroviral integration field has witnessed remarkable advances in recent years. Co-crystal structures of PFV intasomes have revealed unprecedented details of IN-DNA interactions and reaction mechanisms along the complete DNA recombination pathway (13, 18, 26) (Fig. 2 Richet, E., Abcarian, P., and Nash, H.A. Comparison of drug free (left; pdb code 3OY9), RAL (middle; pdb code 3OYA), and DTG-(right; pdb code 3S3M) bound PFV intasomes shows the displacement of the terminal dA nucleotide (carbon, oxygen, and nitrogen atoms are colored magenta, red, and blue, respectively) and the reactive 3'-OH (colored red and marked by black arrowhead) of the transferred DNA strand. (C) IN active sites from the SSC (green; pdb code 4E7I), TCC (cyan; pdb code 4E7K), and RAL-(in pink sticks) bound CDC (pdb code 3OYA) were superimposed using the Cα atoms of active site residues Asp128, Asp185, and Glu221. The unprocessed viral DNA end in the SSC is green while the processed viral DNA and bound target DNA strands from the TCC structure are dark blue and cyan, respectively. Mn 2+ ions (labeled A and B), metal chelating oxygens of RAL, bridging oxygen atoms of the scissile viral DNA and target DNA phosphodiester bonds (black arrowheads), and 3' processing (W nuc ; sphere) and DNA strand transfer (3'-OH; black arrowhead) nucleophiles are colored red to highlight substrate mimicry of INSTIs during retroviral DNA integration (13) . 
